AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05954728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Description: CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
Study NCT05954728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
Description: Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
Study NCT04801693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06289725 — intervention group
Intervention type: DRUG
Intervention: antiviral treatment
Description: The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
Study NCT06480825 — intervention group
Intervention type: OTHER
Intervention: Performance of ultrasonographic scan
Description: Ultra-high frequency ultrasonographic scan of gingival tissues
Study NCT05081934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CRA
Description: 12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
Study NCT05081934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
Study NCT05081934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
Study NCT05935605 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE)
Description: Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
Study NCT05935605 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
Study NCT04952727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
Study NCT04952727 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study NCT05200741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DelNS1-2019-nCoV-RBD-OPT1
Description: Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
Study NCT05200741 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Solution for Intranasal Spray
Study NCT06418464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AP-A Dosage Decision Support System
Description: The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
Study NCT06418464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AP-A Dosage Decision Support System
Description: The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
Study NCT05521776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First-trimester preeclampsia screening (FMF triple test)
Description: An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered.
Study NCT04985396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) group
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
Study NCT04985396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP) group
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
Study NCT06293092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leg pedaling cycling device
Description: Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
Study NCT06293092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sand bags
Description: Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
Study NCT06293092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis sessions
Description: hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
Study NCT04962945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique-axis approach group
Description: The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
Study NCT04962945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis approach group
Description: The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
Study NCT06596018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Target the primary tumor region with a single dose of 8Gy using 6MV-X rays, administered once a day for three consecutive days.
Study NCT06596018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
Study NCT06596018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
Study NCT05826327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The drug esketamine will be added to the experimental group as opposed to the control group.
Study NCT05826327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil for labour analgesia in the control group
Study NCT06366386 — intervention group
Intervention type: BEHAVIORAL
Intervention: Screening and treatment of hypertension among PLHIV in DSD models for HIV
Description: In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
Study NCT06592144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (200mg/3ml)
Description: It will be administered intramuscularly every 5 days, totaling 3 doses.
Study NCT06592144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sesame oil (3ml)
Description: It will be administered intramuscularly every 5 days, totaling 3 doses.
Study NCT05251727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment
Study NCT05251727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weight based dose of reconstituted treatment
Study NCT06590532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair or aorto iliac endovascular revascularisation with Fusion imaging system Cydar-EV
Description: Cydar-EV image fusion is a CE-marked medical device, which instead of a table-tacked overlay uses computer vision to fuse pre-procedural 3D images with intra-operative 2D fluoroscopy automatically and in real-time.
Study NCT06590532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular aneurysm repair or aorto iliac endovascular revascularisation without Fusion imaging system Cydar-EV
Description: patients will be assigned either to an endovascular repair using standard X-ray fluoroscopy imaging alone (the current reference standard)
Study NCT06670053 — intervention group
Intervention type: DRUG
Intervention: Testosterone
Description: Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician.
Study NCT06540716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire System
Description: Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
Study NCT06619184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NCEHFORSCS transplantation
Description: One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
Study NCT05039385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program focused on resistance training
Description: The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise.
Study NCT05845593 — intervention group
Intervention type: OTHER
Intervention: Decision Support Test
Description: LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
Study NCT06093503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion
Study NCT06093503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral: Tablet
Study NCT06093503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion
Study NCT06093503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion
Study NCT06093503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion
Study NCT05581264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education Program
Description: diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
Study NCT05926193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor Food Bags
Description: The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
Study NCT05254210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Device (Potenza™)
Description: Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
Study NCT05645185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis test
Description: Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
Study NCT06619184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPG procedure
Description: Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match
Study NCT06623591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active Transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
Study NCT06623591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcutaneous auricular vagus nerve stimulation
Description: In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
Study NCT05628545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GDKM-100 injection
Description: Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
Study NCT04762966 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Level of Metformin blood concentration
Study NCT06133439 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Colorectal Screen rates with implementation of evidence-based intervention
Description: Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
Study NCT06473428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory muscle training
Description: Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
Study NCT06473428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Training
Description: Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
Study NCT06473428 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Controlled Expiratory Muscle Training
Description: Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
Study NCT06139458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Participants will receive cryotherapy on both hands and feet
Study NCT06139458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compression
Description: Participants will receive compression on both hands and feet
Study NCT05619848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
Study NCT05204979 — intervention group
Intervention type: OTHER
Intervention: Vaginal Versus Sublingual misoprostol
Description: Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
Study NCT04725747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine HCl 3mg-50mg sublingual
Description: Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
Study NCT04725747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 3mg Sublingual
Description: Single sublingual administration of Midazolam 3mg sublingually prior to surgery
Study NCT04725747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50mg Sublingual
Description: Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
Study NCT06289738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICF
Description: Matching the answers given to the question set consisting of 6 open-ended questions with ICF